ZA976697B - Amines for the manufacture of medicinal products intended to prevent the proliferation of tumour cells. - Google Patents

Amines for the manufacture of medicinal products intended to prevent the proliferation of tumour cells.

Info

Publication number
ZA976697B
ZA976697B ZA9706697A ZA976697A ZA976697B ZA 976697 B ZA976697 B ZA 976697B ZA 9706697 A ZA9706697 A ZA 9706697A ZA 976697 A ZA976697 A ZA 976697A ZA 976697 B ZA976697 B ZA 976697B
Authority
ZA
South Africa
Prior art keywords
proliferation
amines
manufacture
prevent
tumour cells
Prior art date
Application number
ZA9706697A
Other languages
English (en)
Inventor
Jean-Claude Breliere
Pascual Ferrara
Christine Lebouteiller
Raymond Paul
Jorge Rosenfeld
Didier Van Broeck
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA976697B publication Critical patent/ZA976697B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
ZA9706697A 1996-07-29 1997-07-28 Amines for the manufacture of medicinal products intended to prevent the proliferation of tumour cells. ZA976697B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9609531A FR2751645B1 (fr) 1996-07-29 1996-07-29 Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales

Publications (1)

Publication Number Publication Date
ZA976697B true ZA976697B (en) 1998-02-10

Family

ID=9494593

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9706697A ZA976697B (en) 1996-07-29 1997-07-28 Amines for the manufacture of medicinal products intended to prevent the proliferation of tumour cells.

Country Status (31)

Country Link
US (1) US6235791B1 (xx)
EP (1) EP0917464B1 (xx)
JP (1) JP3538431B2 (xx)
KR (1) KR100315559B1 (xx)
CN (1) CN1154483C (xx)
AR (1) AR008090A1 (xx)
AT (1) ATE266392T1 (xx)
AU (1) AU735948B2 (xx)
BR (1) BR9711606A (xx)
CA (1) CA2261827C (xx)
CZ (1) CZ294266B6 (xx)
DE (1) DE69729099T2 (xx)
DK (1) DK0917464T3 (xx)
EE (1) EE03851B1 (xx)
ES (1) ES2221061T3 (xx)
FR (1) FR2751645B1 (xx)
HU (1) HU224346B1 (xx)
ID (1) ID17707A (xx)
IL (1) IL127922A (xx)
IS (1) IS2049B (xx)
MY (1) MY120426A (xx)
NO (1) NO322897B1 (xx)
NZ (1) NZ333957A (xx)
PT (1) PT917464E (xx)
RU (1) RU2176502C2 (xx)
SI (1) SI0917464T1 (xx)
SK (1) SK285344B6 (xx)
TR (1) TR199900161T2 (xx)
UA (1) UA61080C2 (xx)
WO (1) WO1998004251A1 (xx)
ZA (1) ZA976697B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2143403B1 (es) * 1998-03-13 2001-01-01 Consejo Superior Investigacion Derivados de ciclopropenilaminas como agentes anticancerosos.
GB9814036D0 (en) 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
FR2794742B1 (fr) 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2795724B1 (fr) * 1999-07-02 2002-12-13 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
ATE327673T1 (de) * 2001-08-23 2006-06-15 Bayer Cropscience Sa Substituierte propargylamine
FR2887454B1 (fr) * 2005-06-28 2009-06-05 Sanofi Aventis Sa Combinaisons antitumorales contenant des derives du taxane et des sigma ligands
AU2007260836B2 (en) 2006-06-23 2012-11-15 Abbvie Bahamas Ltd. Cyclopropyl amine derivatives as histamin H3 receptor modulators
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CA2679882C (en) 2007-03-08 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
KR20150036766A (ko) * 2012-08-01 2015-04-07 머크 샤프 앤드 돔 코포레이션 α7 니코틴성 아세틸콜린 수용체 조절제 및 그의 용도-I
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
EP4213822A1 (en) 2020-09-17 2023-07-26 MELETIOS Therapeutics Compounds for treating virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674832A (en) * 1968-08-22 1972-07-04 Schering Corp Cyclopropane carboxylic acid derivatives
FR2132547A1 (en) * 1971-04-08 1972-11-24 Clin Byla Ets Substd phenyl alkyl or alkenyl amides - useful as analgesics and antiinflammatories
GB1475314A (en) * 1973-11-02 1977-06-01 Cm Ind Phenyl-propylamine derivatives
US4104383A (en) 1973-11-02 1978-08-01 C M Industries Derivatives of phenylpropenylamine
IT1113391B (it) * 1979-05-09 1986-01-20 Maggioni Farma Derivati fenilcicloesanici ad attivita' antidepressiva
US4537902A (en) * 1979-06-11 1985-08-27 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
FR2641276B1 (fr) 1988-12-30 1991-07-12 Sanofi Sa Derives du benzene, leur preparation et les compositions pharmaceutiques en contenant
JP2814694B2 (ja) 1989-07-21 1998-10-27 セイコーエプソン株式会社 識別コード読み書き構造及びその装置及びその方法
FR2663328B1 (fr) * 1990-06-14 1994-08-05 Sanofi Sa Derives d'hexahydroazepines, un procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2694287B1 (fr) * 1992-07-31 1994-09-16 Jouveinal Inst Rech Nouvelles cycloalkylalkylamines ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique.
FR2713639B1 (fr) * 1993-12-09 1996-08-30 Irj Nouveaux dérivés de 2-arylalkényl-azacycloalkanes ligands aux récepteurs sigma, leur procédé de préparation et leur application en thérapeutique.
FR2724656B1 (fr) * 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2725445B1 (fr) * 1994-10-10 1996-10-31 Adir Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5919934A (en) * 1997-02-19 1999-07-06 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Also Published As

Publication number Publication date
JP2000500782A (ja) 2000-01-25
SI0917464T1 (en) 2004-12-31
AR008090A1 (es) 1999-12-09
FR2751645B1 (fr) 1998-12-24
EP0917464A1 (fr) 1999-05-26
KR20000029629A (ko) 2000-05-25
HU9902806A (en) 2000-04-28
AU3855197A (en) 1998-02-20
ATE266392T1 (de) 2004-05-15
IL127922A (en) 2003-11-23
ID17707A (id) 1998-01-22
IS4946A (is) 1999-01-19
NZ333957A (en) 2000-09-29
IL127922A0 (en) 1999-11-30
CA2261827A1 (fr) 1998-02-05
PT917464E (pt) 2004-08-31
DE69729099D1 (de) 2004-06-17
CZ24299A3 (cs) 1999-05-12
EP0917464B1 (fr) 2004-05-12
HU224346B1 (hu) 2005-08-29
EE03851B1 (et) 2002-10-15
WO1998004251A1 (fr) 1998-02-05
BR9711606A (pt) 1999-08-24
DK0917464T3 (da) 2004-08-16
KR100315559B1 (ko) 2001-12-12
NO322897B1 (no) 2006-12-07
NO990401D0 (no) 1999-01-28
FR2751645A1 (fr) 1998-01-30
IS2049B (is) 2005-09-15
CZ294266B6 (cs) 2004-11-10
DE69729099T2 (de) 2005-05-12
NO990401L (no) 1999-03-25
CN1226825A (zh) 1999-08-25
MY120426A (en) 2005-10-31
TR199900161T2 (xx) 1999-04-21
SK7999A3 (en) 2000-01-18
CA2261827C (fr) 2004-10-26
SK285344B6 (sk) 2006-11-03
ES2221061T3 (es) 2004-12-16
AU735948B2 (en) 2001-07-19
JP3538431B2 (ja) 2004-06-14
UA61080C2 (uk) 2003-11-17
EE9900029A (et) 1999-08-16
CN1154483C (zh) 2004-06-23
RU2176502C2 (ru) 2001-12-10
HUP9902806A3 (en) 2000-12-28
US6235791B1 (en) 2001-05-22

Similar Documents

Publication Publication Date Title
ZA976697B (en) Amines for the manufacture of medicinal products intended to prevent the proliferation of tumour cells.
HUT68689A (en) Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors, pharmaceutical compositions containing them, process for producing them and the compositions
EP0659769A3 (en) Means to promote the proliferation of Bifidobacterium.
GR970300037T1 (en) Phenol-derivatives having pharmaceutical activity and process for preparing the same
HUP9901535A3 (en) Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing them
HK1025096A1 (en) Disubstituted bicyclic heterocycles, their production and use as medicaments
HUP0101281A3 (en) Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them
HUP0002921A3 (en) Cyanoguanidines as cell proliferation inhibitors, process for producing them and pharmaceutical compositions containing them
AU2508597A (en) Drug for the treatment of tumours
AU1166895A (en) Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-onederivatives, process for their preparation and the pharmaceutical compositions containing them
IL138247A (en) Substituted bisindolymaleimides for the inhibition of cell proliferation and pharmaceutical compositions comprising them
HUP0104002A3 (en) Alpha2-antagonists tricyclic delta3-piperidines, process for their producing the pharmaceutical compositions containing them and their use as medicament
HUP0101256A3 (en) Pharmaceutical composition having antitumor activity and process for the preparation thereof
HU9700989D0 (en) Ortho-substituted benzoyl-guanidines, process for producing them, their use as medicament and diagnosticment, pharmaceutical compositions containing them
ZA97872B (en) Use of pyrolidine derivatives for the manufacture of medicaments.
HUP0003566A3 (en) Process for producing dosage form and the obtained product
ZA83733B (en) Benzothienylalkylamines,processes for the production and their use as pharmaceuticals
ZA986939B (en) An apparatus for the manufacture of individual holograms to make documents secure.
ZA978219B (en) The production of solid pharmaceutical forms
HUP0203696A3 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation, process for their preparation and pharmaceutical compositions containing them
AU8754098A (en) Pharmaceutical product comprising bacterial strains for the colon therapy
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia
ZA977669B (en) Hydrogen-containing medicinal product.
PL322629A1 (en) Preparation for inhibiting the tumour cells metabolism
FI102037B1 (fi) Menetelmä lääkerakeiden valmistamiseksi